Furno P, Dionisi M S, Bucaneve G, Menichetti F, Del Favero A
Institute of Internal Medicine and Oncological Sciences, Policlinico Monteluce, Perugia, Italy.
Support Care Cancer. 2000 Jul;8(4):293-301. doi: 10.1007/s005200000105.
The object of this work was to compare the efficacy of antibiotic combinations including ceftriaxone with that of combinations including an antipseudomonal beta-lactam for the empirical treatment of febrile neutropenia in cancer patients. We identified all published randomised trials comparing two antibiotic combinations differing only in the beta-lactam, being ceftriaxone in one treatment group and an antipseudomonal beta-lactam in the other. The quality of individual trials was formally evaluated. A meta-analysis was performed using the Peto-modified Mantel-Haenszel method for combining binary data. Primary analysis was done, for both febrile episodes and bacteraemic episodes, using failure of empirical antibiotic treatment defined as modification of the initial allocated regimen or death during treatment. Secondary analysis was done using death from any cause in the two treatment groups. Data relating to 1,537 febrile neutropenic episodes recorded in eight randomised clinical trial were pooled s. Overall, there were 256 treatment failures out of 782 febrile episodes treated with ceftriaxone-containing combinations (32.7%), and 243 out of 755 treated with antipseudomonal beta-lactam regimens (32.1%). The pooled odds ratio of failure for ceftriaxone-containing combinations for febrile episodes was 1.04, with the 95% confidence interval ranging from 0.84 to 1.29, and that for bacteraemic episodes was 0.93 (95% confidence interval 0.58-1.49). With regard to overall mortality, there were 54 deaths among 782 febrile episodes treated with ceftriaxone-containing combinations (6.9%) and 62 deaths among 755 febrile episodes treated with antipseudomonal beta-lactam-containing regimens (8.2%). The pooled odds ratio of death for ceftriaxone regimens was 0.84 (95% confidence interval 0.57-1.24). Results of this meta-analysis show that in the empirical treatment of febrile neutropenia, antibiotic combinations containing ceftriaxone are as effective as those in which the beta-lactam has specific activity against Pseudomonas aeruginosa, such as ureidopenicillin or ceftazidime.
这项工作的目的是比较含头孢曲松的抗生素联合用药与含抗假单胞菌β-内酰胺类抗生素的联合用药在癌症患者发热性中性粒细胞减少症经验性治疗中的疗效。我们检索了所有已发表的随机试验,这些试验比较了两种仅在β-内酰胺类抗生素上存在差异的抗生素联合用药,一个治疗组使用头孢曲松,另一个治疗组使用抗假单胞菌β-内酰胺类抗生素。对各个试验的质量进行了正式评估。采用Peto修正的Mantel-Haenszel方法对二元数据进行合并,进行了荟萃分析。对于发热发作和菌血症发作,主要分析采用经验性抗生素治疗失败作为指标,经验性抗生素治疗失败定义为改变初始分配的治疗方案或治疗期间死亡。次要分析采用两个治疗组中任何原因导致的死亡情况。汇总了八项随机临床试验中记录的1537例发热性中性粒细胞减少症发作的数据。总体而言,在使用含头孢曲松联合用药治疗的782例发热发作中,有256例治疗失败(32.7%),在使用抗假单胞菌β-内酰胺类治疗方案治疗的755例中,有243例治疗失败(32.1%)。含头孢曲松联合用药治疗发热发作失败的汇总比值比为1.04,95%置信区间为0.84至1.29,菌血症发作的汇总比值比为0.93(95%置信区间0.58 - 1.49)。关于总体死亡率,在使用含头孢曲松联合用药治疗的782例发热发作中有54例死亡(6.9%),在使用含抗假单胞菌β-内酰胺类治疗方案治疗的755例发热发作中有62例死亡(8.2%)。头孢曲松治疗方案死亡的汇总比值比为0.84(95%置信区间0.